At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 542 enrolled
Drug / intervention
AZD6765 iv +2 moredrug
Likely dose
AZD6765 iv 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants
In Brief
A Phase 2 clinical trial evaluating AZD6765 iv and Placebo for Major Depressive Disorder. Completed, enrolled 542 participants across 44 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesChile, Slovakia, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionAug 2013
TodayJul 2026
First PostedNov 30, 2011
Enrollment StartDec 16, 2011
Primary CompletionAug 26, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.6 years ago
Interventions
AZD6765 ivdrug
50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
AZD6765 ivdrug
100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
Placebodrug
0.9 sodium chloride \[normal saline\] solution for injection by iv infusion